Biotechnology

Pharmaceuticals

The End of Lifelong Treatment: What GSK's Hibsago Approval Means for Chronic Hepatitis B

GSK's Hibsago approval marks a breakthrough in hepatitis B treatment, offering the first realistic path to functional cure for a subset of patients—a fundamental shift from decades of indefinite antiviral therapy.

Pharmaceuticals

The Functional Cure That Took Fifty Years: What GSK's Hibsago Approval Means for Hepatitis B

The FDA's approval of Hibsago marks a watershed moment in hepatitis B treatment, offering the first functional cure for a disease that has resisted curative approaches for fifty years. A 20% cure rate represents a genuine discontinuity from the chronic management paradigm that has defined the field.

Policy

Beijing Draws a Line: What China's Proposed Biopharma Export Ban Means for the Global Deal Machine

China's proposed ban on foreign acquisitions of advanced biotech platforms marks a significant shift in how Beijing views its biotech sector, though out-licensing deals remain unaffected.

Pharmaceuticals

Surgery-Free and Cancer-Gone: What GSK's Jemperli Approval Means for Rectal Cancer Treatment

On October 19, 2026, the FDA granted accelerated approval to GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). The approval is narrow in scope, applying to

Policy

China Draws a Line Around Its Biotech Crown Jewels

China's new technology export restrictions aim to prevent foreign acquisition of key biotech platforms while permitting licensing arrangements, marking a shift toward more managed cross-border biotech dealmaking.

Policy

Rewriting the Rules: What the FDA's Rare Disease Framework Initiative Means for Drug Development

The FDA's new Rare Disease Framework Initiative proposes to make fit-for-purpose evidentiary standards the default for rare disease drug development. Here is what it means and why it matters.

Biotechnology

The Shot That Reaches the Brain: What Arrowhead's ARO-MAPT Data Mean for Alzheimer's and the Future of RNA Medicine

Arrowhead's ARO-MAPT data demonstrate that subcutaneous injection can deliver siRNA across the blood-brain barrier, reducing tau protein by up to 85% in healthy volunteers—a potential breakthrough for Alzheimer's and RNA medicine.

Biotechnology

Fixed Versus Flexible: What BioNTech's mRNA Cancer Vaccine Failure Reveals About the Road Ahead

BioNTech's mRNA cancer vaccine BNT113 failed to meet its primary endpoint in a Phase 2/3 trial, raising critical questions about fixed antigen approaches versus personalized vaccines in the future of cancer immunotherapy.

Biotechnology

Alpha Strikes Back: What RYZ101's Phase 3 Win Means for the Future of Radiopharmaceutical Therapy

Bristol Myers Squibb's RYZ101 becomes the first alpha-emitting radiopharmaceutical to succeed in a Phase 3 trial. What the ACTION-1 result means for the future of targeted radiation therapy in GEP-NETs and beyond.

Pharmaceuticals

Chemotherapy-Free and Moving Earlier: What Pfizer's Tukysa Approval Means for HER2-Positive Breast Cancer

FDA approves Pfizer's Tukysa (tucatinib) for maintenance treatment of HER2-positive metastatic breast cancer, offering chemotherapy-free disease control with a median PFS benefit of 8.5 months.

Biotechnology

Light as Medicine: What the Nobel Prize for Optogenetics Means for the Future of Brain Therapies

The 2026 Nobel Prize in Medicine went to the pioneers of optogenetics. With the first optogenetic therapy approaching FDA approval and psychiatric applications in clinical trials, the prize marks a turning point for neuroscience drug development.

Biotechnology

The Bispecific That Beat R-CHOP: What Epkinly's First-Line DLBCL Win Means for the Future of Lymphoma Treatment

AbbVie and Genmab's epcoritamab (Epkinly) met its primary endpoint in the Phase 3 Epcore DLBCL-2 trial, reducing disease progression or death risk by 51% compared to R-CHOP alone in newly diagnosed DLBCL. This result challenges Roche's Polivy's dominance in the first-line setting.